References
1. A Vaglio, C Buzio, J Zwerina. Eosinophilic granulomatosis with
polyangiitis (Churg-Strauss): state of the art. Allergy .
2013;68(3):261-273.
2. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for
Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med .
2017;376(20):1921-1932.
3. Kato A, Peters A, Suh L, et al. Evidence of a role for B
cell-activating factor of the TNF family in the pathogenesis of chronic
rhinosinusitis with nasal polyps. J Allergy Clin Immunol .
2008;121(6):1385-1392, 1392.e1-2.
4. Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic
diseases: From bench to clinic - Contribution of the discovery of
interleukin-5. Cytokine . 2017;98:59-70.
5. Ramponi G, Folci M, De Santis M, et al. The biology, pathogenetic
role, clinical implications, and open issues of serum anti-neutrophil
cytoplasmic antibodies. Autoimmun Rev . 2021;20(3):102759.
6. Fukuchi M, Kamide Y, Ueki S, et al. Eosinophil ETosis-Mediated
Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis.Arthritis Rheumatol . 2021;73(9):1683-1693.